Physician

Karen Ann Finkelstein, MD

According to 2025 Medicare claims, Karen Finkelstein, MD (NPI: 1881643989) practices gynecologist/oncologist in the Albuquerque, NM market, with the plurality of this provider's patient population coming from Bernalillo, NM. This provider's primary affiliated billing organization is SOUTHWEST WOMEN'S ONCOLOGY INC. (NPI: 1942372479; TIN: 850405838) and primary practice location at 87109-3573. Finkelstein is affiliated with the Caravan Collaborative Pathways (ACO ID: A4604), participating under the MSSP model.

Finkelstein's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 431 traditional Medicare patients, billed 44,482 HCPCS/CPT codes, and received $901,458 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 723 prescription claims across 217 beneficiaries totaling $276,733 in drug costs, led by Everolimus (Everolimus). 2023 DME data shows 11 claims. Open Payments data shows 51 records totaling $446,054. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $1,020,555 to $901,458. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $178,808 and ending at $276,733. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $956 and ending at $9,129.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	348	26,826	$1,020,555
2016	416	29,828	$1,318,131
2017	469	30,862	$1,368,675
2018	384	67,421	$1,315,872
2019	432	65,717	$1,241,056
2020	395	81,767	$1,288,600
2021	411	69,169	$1,077,904
2022	415	60,104	$782,361
2023	426	44,324	$812,581
2024	431	44,482	$901,458

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	178	746	$178,808
2016	192	1,109	$54,169
2017	186	933	$57,807
2018	137	719	$273,075
2019	184	732	$1,148,268
2020	213	773	$922,749
2021	232	766	$874,689
2022	223	788	$347,733
2023	218	831	$557,422
2024	217	723	$276,733

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	15	$1,785
2017	N/R	22	$1,836
2018	N/R	12	$258
2019	N/R	34	$4,927
2020	N/R	37	$3,403
2021	N/R	73	$7,550
2022	N/R	N/R	N/R
2023	N/R	11	$327
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	80	80	$172
96413	Administration of chemotherapy into vein, 1 hour or less	44	134	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	285	474	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	43	44	$61
96375	Injection of additional new drug or substance into vein	40	261	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Everolimus	Everolimus	21	592	$59,998
Estradiol	Estradiol	18	1,518	$3,172
Naloxone Hcl	Naloxone Hcl	28	174	$1,905
Megestrol Acetate	Megestrol Acetate	29	785	$1,046
Ondansetron Odt	Ondansetron	13	143	$842

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	47	$7,111	INTUITIVE SURGICAL, INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$438,943	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Karen Ann Finkelstein, MD?

Tedicare shows public-source Medicare data for Karen Ann Finkelstein, MD (NPI 1881643989), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Karen Ann Finkelstein, MD have ACO affiliation data?

Karen Ann Finkelstein, MD is shown with ACO affiliation data for Caravan Collaborative Pathways (MSSP, ACO ID A4604).

What billing organization is linked to Karen Ann Finkelstein, MD?

Karen Ann Finkelstein, MD is linked to SOUTHWEST WOMEN'S ONCOLOGY INC. (billing NPI 1942372479) in the available physician profile data.

Does Karen Ann Finkelstein, MD have Open Payments data?

Karen Ann Finkelstein, MD has 51 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.